Paroxysmal Atrial Fibrillation
Conditions
Keywords
cryoablation
Brief summary
To establish the safety and effectiveness of the Boston Scientific Cardiac Cryoablation System for treatment of symptomatic, drug refractory, recurrent, paroxysmal atrial fibrillation (AF).
Detailed description
Multi-center, open label, prospective, single arm study to document the safety and performance of Boston Scientific's Cryoablation System. The Cryoablation System is intended for cryoablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF). All subjects fitting the enrollment criteria, signing the consent and undergoing the index procedure with the study devices will be followed up for twelve (12) months after the index procedure.
Interventions
The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following: * POLARx™ or POLARx™ FIT Cryoablation Catheter * POLARMAP™ Catheter * POLARSHEATH™ * SMARTFREEZE™ Console * Diaphragm Movement Sensor (DMS) * Related Accessories
Sponsors
Boston Scientific Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
open label, prospective, single arm study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* History of recurrent symptomatic paroxysmal atrial fibrillation (PAF), defined as atrial fibrillation that terminates spontaneously or with intervention (either procedure or drug therapy) within seven days of onset. Minimum documentation includes the following: * a physician's note indicating recurrent self-terminating atrial fibrillation (AF) which includes at least two symptomatic AF episodes within six months prior to enrollment, and one electrocardiographically documented AF episode within 12 months prior to enrollment. * No amiodarone use within 90 days prior to enrollment; * Subjects who are indicated for an ablation procedure for paroxysmal atrial fibrillation (PAF) according to 2017 HRS expert consensus statement on catheter and surgical ablation of atrial fibrillation; * Subjects refractory or intolerant to at least one class I or III antiarrhythmic medication; * Subjects who are willing and capable of providing informed consent; * Subjects who are willing and capable of participating in all testing associated with this clinical investigation at an approved clinical investigational center; * Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.
Exclusion criteria
* Any known contraindication to an AF ablation or anticoagulation; * Continuous AF lasting longer than seven (7) days from onset; * History of previous left atrial ablation or surgical treatment for AF/ AFL/ AT; * Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiac cause; * Structural heart disease or implanted devices as described below: 1. Left ventricular ejection fraction (LVEF) \< 40% based on the most recent transthoracic echocardiogram (TTE) (≤180 days prior to enrollment); 2. Left atrial diameter \> 55 mm OR left atrial volume \> 50 ml/m2 ml indexed based on the most recent TTE (≤ 180 days prior to enrollment); 3. An implanted pacemaker, ICD, CRT device or an arrhythmia loop recorder; 4. Previous cardiac surgery: i.e. ventriculotomy or atriotomy (excluding atriotomy for CABG); 5. Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve, including mitral valve clips; 6. Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occlude; 7. Presence of a left atrial appendage occlusion device; 8. Presence of any pulmonary vein stents; 9. Coronary artery bypass graft (CABG), PTCA/ PCI/ coronary stent procedures within 90 days prior to enrollment; 10. Unstable angina or ongoing myocardial ischemia; 11. myocardial infarction within 90 days prior to enrollment; 12. Moderate or severe mitral insufficiency assessed on the most recent TTE (≤180 days prior to enrollment, e.g. pulmonary artery pressure \>30 mmHg); 13. Evidence of left atrial thrombus; * Any previous history of cryoglobulinemia; * Stage 3B or higher renal disease (estimated glomerular filtration rate, eGFR \<45 mL/min); * History of blood clotting or bleeding disease; * Any prior history of documented cerebral infarct, TIA or systemic embolism \[excluding a post-operative deep vein thrombosis (DVT)\] ≤180 days prior to enrollment; * Active systemic infection; * Pregnant, lactating (current or anticipated during study follow up), or women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion); * Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the sponsor to determine eligibility; * Subjects who in the judgment of the investigator have a life expectancy of less than two years.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Acute Procedural Success Defined as the Achievement of Electrical Isolation of All PVs by Using the Boston Scientific Cardiac Cryoablation System With POLARx Fit Cryoablation Balloon Catheter Models | 1 day | The primary effectiveness endpoint is the rate of acute procedural success where acute procedural success is defined as the achievement of electrical isolation of all PVs by using the Cardiac Cryoablation System with the POLARx FIT cryoablation balloon catheter models (with treatment applied at 28 mm or 31 mm balloon size per physician discretion). Electrical isolation of a PV is demonstrated by entrance and exit block. |
| Percentage of Participants With Freedom From Primary Safety Events at 12 Months Post-procedure (Acute and Chronic Events) Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models | 12 Months | This measure reports the observed safety event-free rate at 12 Months follow up for all Non Roll-In treatment and intent subjects. The safety events are a composite of procedure-related and device-related adverse events. 7 days (Death, Myocardial infarction, Transient ischemic attack, Stroke/ Cerebrovascular accident, Vascular access complications, Mitral or tricuspid valvular damage, Thromboembolism/ Air embolism leading to a life-threatening event such as a ventricular arrhythmia, stroke, pulmonary embolism, or myocardial infarction and, thromboembolic events that result in permanent injury, require intervention for treatment or prolongs or require hospitalization for more than 48 hours, Gastroparesis/injury to vagus nerve, Pneumothorax, Pulmonary edema/heart failure AV block); 30 days (Cardiac tamponade/perforation); 12 months: (Atrial esophageal fistula, Severe Pulmonary vein stenosis, Persistent phrenic nerve palsy . |
| Percentage of Participants With Freedom From Treatment Failure at 12 Months Post-procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models | 12 Months | Freedom from the composite of: Failure to achieve acute procedural success in the index procedure or repeat procedure during the blanking period; Use of amiodarone post index procedure; Surgical treatment for AF/AFL/AT post index procedure; Use of non-study ablation catheter for AF targets in the index procedure or repeat procedure during the blanking period; More than one repeat procedure with the POLARx catheter during the blanking period (90 days post index procedure); Documented AF, or new onset of AF or AT event 91-365 days post index procedure; Any of the following for AF, or new onset of AF or AT 91-365 days post index procedure: Repeat procedure - Electrical and/or pharmacological cardioversion for AF/AFL/AT - Prescribed AAD consisting of any Class I/III, including Amiodarone, and any Class II/IV medications taken for control of AF, AT, AFL recurrence |
| Percentage of Participants With Freedom From Primary Safety Events at 3 Months Post Procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx FIT Cryoablation Balloon Catheter Models | 3 months | Composite of procedure-related and device-related adverse events. 7 days post index procedure or hospital discharge, whichever is later, unless denoted as events counting through 3 months post index procedure (Death, Myocardial infarction, Major Vagal Nerve Injury/Gastroparesis, Transient ischemic attack, Stroke/Cerebrovascular accident, Thromboembolism, Cardiac tamponade/perforation, Pneumothorax, Major vascular access complications, Pulmonary edema/heart failure, AV block, Atrial esophageal fistula, severe pulmonary vein stenosis (≥70% reduction in the diameter of the PV or PV branch from baseline), Persistent phrenic nerve palsy) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Freedom From Treatment Failure at 12 Months Post-procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx FIT Cryoablation Balloon Catheter Models | 12 Months | Freedom from the composite of: Failure to achieve acute procedural success in the index procedure or repeat procedure during the blanking period; Use of amiodarone post index procedure; Surgical treatment for AF/AFL/AT post index procedure; Use of non-study ablation catheter for AF targets in the index procedure or repeat procedure during the blanking period; More than one repeat procedure with the Cryoablation System during the blanking period (90 days post index procedure); Documented AF, or new onset of AF or AT event 91-365 days post index procedure; Any of the following for AF, or new onset of AF or AT 91-365 days post index procedure: Repeat procedure - Electrical and/or pharmacological cardioversion for AF/AFL/AT - Prescribed AAD consisting of any Class I/III, including Amiodarone, and any Class II/IV medications taken for control of AF, AT, AFL recurrence |
| Percentage of Participants With Acute Procedural Success Defined as the Achievement of Electrical Isolation of All PVs by Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter | 1 day | The achievement of electrical isolation of all PVs by using the POLARx Cardiac Cryoablation System. Electrical isolation of a PV is demonstrated by entrance and exit block. |
| Number of Participants With Freedom From Reportable Adverse Events at 12 Months Post Procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models | 12 months | * All Serious Adverse Events * All Study Procedure-Related Adverse Events * All Study Device-Related Adverse Events * All Study Device Deficiencies * Unanticipated Adverse Device Effects/Unanticipated Serious Adverse Device Effects previously not defined in Investigator's Brochure or DFU |
| Percentage of Participants With Freedom From Safety Events at 12 Months Post Procedure Using the Boston Scientific Cardiac Cryoablation System Using the Boston Scientific Cardiac Cryoablation System With POLARx FIT Cryoablation Balloon Catheter Models | 12 Months | The following events will be counted through 7 days post index procedure or hospital discharge, whichever is later: Death, Myocardial infarction, Major Vagal Nerve Injury/Gastroparesis, Transient ischemic attack, Stroke/Cerebrovascular accident, Thromboembolism, Pneumothorax, Major vascular access complications, Pulmonary edema/heart failure, AV block. The following event will be counted through 30 days post index procedure: Cardiac tamponade/perforation. The following events will be counted through 12 months post index procedure: Atrial esophageal fistula, Severe pulmonary vein stenosis (≥70% reduction in the diameter of the PV or PV branch from baseline), Persistent phrenic nerve palsy. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Freedom From Recurrence | 12 Months | The following analysis looks at the recurrence free rate of individual atrial arrhythmia types as documented on a rhythm monitoring device post- blanking period. |
Countries
Belgium, Canada, France, Germany, Hong Kong, Italy, Netherlands, Taiwan, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| FROzEN Non Roll-In Treatment Subjects Subjects undergoing cardiac ablation procedure with the Boston Scientific Cardiac Cryoablation System
Boston Scientific Cardiac Cryoablation System: The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:
* POLARx™ or POLARx FIT Cryoablation Catheter
* POLARMAP™ Catheter
* POLARSHEATH™
* SMARTFREEZE™ Console
* Diaphragm Movement Sensor (DMS)
* Related Accessories | 325 |
| POLARx FIT Sub-study Subjects undergoing cardiac ablation procedure with the Boston Scientific Cardiac Cryoablation System
Boston Scientific Cardiac Cryoablation System: The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:
* POLARx™ or POLARx FIT Cryoablation Catheter
* POLARMAP™ Catheter
* POLARSHEATH™
* SMARTFREEZE™ Console
* Diaphragm Movement Sensor (DMS)
* Related Accessories | 50 |
| Total | 375 |
Baseline characteristics
| Characteristic | Total | POLARx FIT Sub-study | FROzEN Non Roll-In Treatment Subjects |
|---|---|---|---|
| Age, Continuous | 62 years STANDARD_DEVIATION 11 | 64 years STANDARD_DEVIATION 13 | 62 years STANDARD_DEVIATION 11 |
| BMI | 29 kg/m^2 STANDARD_DEVIATION 6 | 31 kg/m^2 STANDARD_DEVIATION 7 | 29 kg/m^2 STANDARD_DEVIATION 6 |
| CHA2DS2-VASc Score 0 | 66 Participants | 3 Participants | 63 Participants |
| CHA2DS2-VASc Score 1 | 97 Participants | 15 Participants | 82 Participants |
| CHA2DS2-VASc Score 2 | 108 Participants | 16 Participants | 92 Participants |
| CHA2DS2-VASc Score 3 | 64 Participants | 5 Participants | 59 Participants |
| CHA2DS2-VASc Score 4 | 27 Participants | 6 Participants | 21 Participants |
| CHA2DS2-VASc Score 5 | 12 Participants | 4 Participants | 8 Participants |
| CHA2DS2-VASc Score 6 | 1 Participants | 1 Participants | 0 Participants |
| Diastolic BP | 79 mmHg STANDARD_DEVIATION 11 | 76 mmHg STANDARD_DEVIATION 9 | 79 mmHg STANDARD_DEVIATION 11 |
| Height | 174 cm STANDARD_DEVIATION 10 | 173 cm STANDARD_DEVIATION 10 | 174 cm STANDARD_DEVIATION 10 |
| Pulse | 67 bpm STANDARD_DEVIATION 14 | 66 bpm STANDARD_DEVIATION 13 | 67 bpm STANDARD_DEVIATION 14 |
| Race/Ethnicity, Customized Asian | 35 Participants | 0 Participants | 35 Participants |
| Race/Ethnicity, Customized Black | 5 Participants | 1 Participants | 4 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 5 Participants | 0 Participants | 5 Participants |
| Race/Ethnicity, Customized Native American | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Other | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Undisclosed | 12 Participants | 0 Participants | 12 Participants |
| Race/Ethnicity, Customized White | 323 Participants | 49 Participants | 274 Participants |
| Sex: Female, Male Female | 147 Participants | 23 Participants | 124 Participants |
| Sex: Female, Male Male | 228 Participants | 27 Participants | 201 Participants |
| Systolic BP | 133 mmHg STANDARD_DEVIATION 18 | 134 mmHg STANDARD_DEVIATION 16 | 133 mmHg STANDARD_DEVIATION 18 |
| Weight | 87 kg STANDARD_DEVIATION 20 | 93 kg STANDARD_DEVIATION 22 | 86 kg STANDARD_DEVIATION 19 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 336 | 1 / 60 | 0 / 50 |
| other Total, other adverse events | 86 / 326 | 16 / 60 | 5 / 50 |
| serious Total, serious adverse events | 33 / 326 | 10 / 60 | 4 / 50 |
Outcome results
Primary
Percentage of Participants With Acute Procedural Success Defined as the Achievement of Electrical Isolation of All PVs by Using the Boston Scientific Cardiac Cryoablation System With POLARx Fit Cryoablation Balloon Catheter Models
The primary effectiveness endpoint is the rate of acute procedural success where acute procedural success is defined as the achievement of electrical isolation of all PVs by using the Cardiac Cryoablation System with the POLARx FIT cryoablation balloon catheter models (with treatment applied at 28 mm or 31 mm balloon size per physician discretion). Electrical isolation of a PV is demonstrated by entrance and exit block.
Time frame: 1 day
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FROzEN Non Roll-In Subjects | Percentage of Participants With Acute Procedural Success Defined as the Achievement of Electrical Isolation of All PVs by Using the Boston Scientific Cardiac Cryoablation System With POLARx Fit Cryoablation Balloon Catheter Models | 100 Percentage of participants |
Primary
Percentage of Participants With Freedom From Primary Safety Events at 12 Months Post-procedure (Acute and Chronic Events) Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models
This measure reports the observed safety event-free rate at 12 Months follow up for all Non Roll-In treatment and intent subjects. The safety events are a composite of procedure-related and device-related adverse events. 7 days (Death, Myocardial infarction, Transient ischemic attack, Stroke/ Cerebrovascular accident, Vascular access complications, Mitral or tricuspid valvular damage, Thromboembolism/ Air embolism leading to a life-threatening event such as a ventricular arrhythmia, stroke, pulmonary embolism, or myocardial infarction and, thromboembolic events that result in permanent injury, require intervention for treatment or prolongs or require hospitalization for more than 48 hours, Gastroparesis/injury to vagus nerve, Pneumothorax, Pulmonary edema/heart failure AV block); 30 days (Cardiac tamponade/perforation); 12 months: (Atrial esophageal fistula, Severe Pulmonary vein stenosis, Persistent phrenic nerve palsy .
Time frame: 12 Months
Population: Non Roll-In Treatment and intent Subjects
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FROzEN Non Roll-In Subjects | Percentage of Participants With Freedom From Primary Safety Events at 12 Months Post-procedure (Acute and Chronic Events) Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models | 96 Percentage of participants |
Primary
Percentage of Participants With Freedom From Primary Safety Events at 3 Months Post Procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx FIT Cryoablation Balloon Catheter Models
Composite of procedure-related and device-related adverse events. 7 days post index procedure or hospital discharge, whichever is later, unless denoted as events counting through 3 months post index procedure (Death, Myocardial infarction, Major Vagal Nerve Injury/Gastroparesis, Transient ischemic attack, Stroke/Cerebrovascular accident, Thromboembolism, Cardiac tamponade/perforation, Pneumothorax, Major vascular access complications, Pulmonary edema/heart failure, AV block, Atrial esophageal fistula, severe pulmonary vein stenosis (≥70% reduction in the diameter of the PV or PV branch from baseline), Persistent phrenic nerve palsy)
Time frame: 3 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FROzEN Non Roll-In Subjects | Percentage of Participants With Freedom From Primary Safety Events at 3 Months Post Procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx FIT Cryoablation Balloon Catheter Models | 100 Percentage of participants |
Primary
Percentage of Participants With Freedom From Treatment Failure at 12 Months Post-procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models
Freedom from the composite of: Failure to achieve acute procedural success in the index procedure or repeat procedure during the blanking period; Use of amiodarone post index procedure; Surgical treatment for AF/AFL/AT post index procedure; Use of non-study ablation catheter for AF targets in the index procedure or repeat procedure during the blanking period; More than one repeat procedure with the POLARx catheter during the blanking period (90 days post index procedure); Documented AF, or new onset of AF or AT event 91-365 days post index procedure; Any of the following for AF, or new onset of AF or AT 91-365 days post index procedure: Repeat procedure - Electrical and/or pharmacological cardioversion for AF/AFL/AT - Prescribed AAD consisting of any Class I/III, including Amiodarone, and any Class II/IV medications taken for control of AF, AT, AFL recurrence
Time frame: 12 Months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FROzEN Non Roll-In Subjects | Percentage of Participants With Freedom From Treatment Failure at 12 Months Post-procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models | 59.9 Percentage of participants |
Secondary
Number of Participants With Freedom From Reportable Adverse Events at 12 Months Post Procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models
* All Serious Adverse Events * All Study Procedure-Related Adverse Events * All Study Device-Related Adverse Events * All Study Device Deficiencies * Unanticipated Adverse Device Effects/Unanticipated Serious Adverse Device Effects previously not defined in Investigator's Brochure or DFU
Time frame: 12 months
Population: The total population represents all Non-Roll In (336) and Roll in (63) enrolled subjects.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| FROzEN Non Roll-In Subjects | Number of Participants With Freedom From Reportable Adverse Events at 12 Months Post Procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models | 254 Participants |
Secondary
Percentage of Participants With Acute Procedural Success Defined as the Achievement of Electrical Isolation of All PVs by Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter
The achievement of electrical isolation of all PVs by using the POLARx Cardiac Cryoablation System. Electrical isolation of a PV is demonstrated by entrance and exit block.
Time frame: 1 day
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FROzEN Non Roll-In Subjects | Percentage of Participants With Acute Procedural Success Defined as the Achievement of Electrical Isolation of All PVs by Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter | 95.69 Percentage of participants |
Secondary
Percentage of Participants With Freedom From Safety Events at 12 Months Post Procedure Using the Boston Scientific Cardiac Cryoablation System Using the Boston Scientific Cardiac Cryoablation System With POLARx FIT Cryoablation Balloon Catheter Models
The following events will be counted through 7 days post index procedure or hospital discharge, whichever is later: Death, Myocardial infarction, Major Vagal Nerve Injury/Gastroparesis, Transient ischemic attack, Stroke/Cerebrovascular accident, Thromboembolism, Pneumothorax, Major vascular access complications, Pulmonary edema/heart failure, AV block. The following event will be counted through 30 days post index procedure: Cardiac tamponade/perforation. The following events will be counted through 12 months post index procedure: Atrial esophageal fistula, Severe pulmonary vein stenosis (≥70% reduction in the diameter of the PV or PV branch from baseline), Persistent phrenic nerve palsy.
Time frame: 12 Months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FROzEN Non Roll-In Subjects | Percentage of Participants With Freedom From Safety Events at 12 Months Post Procedure Using the Boston Scientific Cardiac Cryoablation System Using the Boston Scientific Cardiac Cryoablation System With POLARx FIT Cryoablation Balloon Catheter Models | 100 Percentage of participants |
Secondary
Percentage of Participants With Freedom From Treatment Failure at 12 Months Post-procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx FIT Cryoablation Balloon Catheter Models
Freedom from the composite of: Failure to achieve acute procedural success in the index procedure or repeat procedure during the blanking period; Use of amiodarone post index procedure; Surgical treatment for AF/AFL/AT post index procedure; Use of non-study ablation catheter for AF targets in the index procedure or repeat procedure during the blanking period; More than one repeat procedure with the Cryoablation System during the blanking period (90 days post index procedure); Documented AF, or new onset of AF or AT event 91-365 days post index procedure; Any of the following for AF, or new onset of AF or AT 91-365 days post index procedure: Repeat procedure - Electrical and/or pharmacological cardioversion for AF/AFL/AT - Prescribed AAD consisting of any Class I/III, including Amiodarone, and any Class II/IV medications taken for control of AF, AT, AFL recurrence
Time frame: 12 Months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FROzEN Non Roll-In Subjects | Percentage of Participants With Freedom From Treatment Failure at 12 Months Post-procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx FIT Cryoablation Balloon Catheter Models | 78 Percentage of participants |
Other Pre-specified
Percentage of Participants With Freedom From Recurrence
The following analysis looks at the recurrence free rate of individual atrial arrhythmia types as documented on a rhythm monitoring device post- blanking period.
Time frame: 12 Months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FROzEN Non Roll-In Subjects | Percentage of Participants With Freedom From Recurrence | 79.9 Percentage of participants |
Post Hoc
Percentage of Participants With Freedom From Treatment Failure With Updated AAD Definition at 12 Months Post-procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models
In this sensitivity analysis, subjects were counted as primary effectiveness failures only if they were taking a new AAD not prescribed prior to index procedure or a higher dose of an AAD than they were previously prescribed.
Time frame: 12 Months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| FROzEN Non Roll-In Subjects | Percentage of Participants With Freedom From Treatment Failure With Updated AAD Definition at 12 Months Post-procedure Using the Boston Scientific Cardiac Cryoablation System With POLARx Cryoablation Balloon Catheter Models | 71.6 Percentage of participants |